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Background: In cervical cancer patients with intermediate-risk factors, the optimal adjuvant therapy is still controversial.
We undertook a randomized trial (ClinicalTrials.gov Identifier: NCT01418859) to compare the efficacy and toxicity of
concurrent chemoradiotherapy with topotecan and cisplatin with radiotherapy alone in intermediate-risk cervical
cancer patients.
Methods: Eligible patients were randomly assigned to one of three treatment arms including arm A (radiotherapy
only,RT), arm B(concurrent chemoradiotherapy only, CCRT), and arm C (concurrent chemoradiotherapy with following
consolidation chemotherapy, CCRT + CT). All eligible patients completed external RT (IMRT or 3D-CRT), receiving
45-50Gy /25f uniformly to the pelvis. Concurrent chemotherapy regimen was topotecan 0.75 mg/m2 for days 1, 2
and 3, followed by cisplatin 25 mg/m2 for days 1, 2 and 3. Three cycles of consolidation chemotherapy regimen
was topotecan 1.5 mg/m2 for days 1 and 2, and 0.75 mg/m2 for day 3; followed by cisplatin 25 mg/m2 for days
1, 2 and 3, repeated every 21 days. Adverse events of each group were investigated and compared.
Results: Thirty-nine patients enrolled onto the remaining regimens: 14 to RT, 15 to CCRT and 10 to CCRT + CT.
Six patients (15.4%) did not complete the protocol treatment. Hematologic toxicity was more frequent and more
severe in the CCRT and CCRT + CT arms compared with the RT arm. The incidence of grade 3-4 neutropenia was
significantly different statistically between the RT, CCRT and CCRT + RT groups (15.4%, 46.7% and 100%, respectively;
P = 0.002). Specially, three patients in CCRT + CT arm of all six patients who did not complete the protocol treatment
discontinued planned therapy because of persistent grade 4 neutropenia. However, there were no significant differences
in grade 3-4 non-hematologic toxicities between the three groups(all P > 0.05). Recurrence-free survival and overall
survival of each group were not analyzed on account of a median follow-up of only 16 months.
Conclusions: Concurrent chemoradiotherapy with topotecan and cisplatin showed severe hematologic toxicity in
intermediate-risk cervical cancer patients after radical hysterectomy. Thus, the study was closed ahead of schedule.
Trial registration: ClinicalTrials.gov Identifier: NCT01418859.
Keywords: Chemoradiotherapy, Topotecan, Cisplatin, Intermediate-risk, Cervical cancer* Correspondence: liuzmail@163.com
Department of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong
University, 277 Yanta West Road, Yanta District, Xi’an 710061, China
© 2015 Sun et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Sun et al. BMC Cancer  (2015) 15:353 Page 2 of 7Background
Radical hysterectomy with pelvic lymphadenectomy has
been widely accepted as treatment in patients with stage
IB-IIA cervical cancer. However, the survival of patients
with early stage cervical cancer after radical hysterec-
tomy and pelvic lymphadenectomy depends on the
presence or absence of several poor prognostic clinico-
pathologic risk factors. Positive or close resection mar-
gin, lymph node involvement, and parametrial invasion
were recognized as high-risk factors while large tumor
size, deep stromal invasion, and lymphovascular space
invasion (LVSI) were regarded as intermediate-risk
factors [1].
Radiation has been used as a postoperative adjuvant
therapy to reduce recurrences in cervical cancer patients
with both these intermediate and high risk factors [2-5].
Since Peters et al. showed a significant survival advan-
tage with the use of concurrent chemoradiation rather
than radiation in patients with high-risk cervical cancer
[6]. Concurrent chemoradiation rapidly replaced radi-
ation in the treatment of high-risk cervical cancer [6-8].
Although radiotherapy has been used as postoperative
adjuvant therapy to reduce recurrence and improve sur-
vival in patients with intermediate risk tumors and the
effectiveness of radiotherapy has been widely accepted,
based on the results of a randomized study reported by
Sedlis et al. [9]. Recent retrospective studies insisted that
adjuvant radiotherapy may have local effects only, which
are not effective in distant recurrence and have sug-
gested the promising improvements of adding chemo-
therapy to radiation in patients with intermediate-risk
factors [10-12]. Thus, two practical debates still re-
main regarding for the adjuvant treatment of the
intermediate-risk group. First, is whether concurrent
chemoradiotherapy (CCRT), which has been estab-
lished as a standard adjuvant treatment of high-risk
cervical cancer, is more beneficial than radiotherapy only
for an intermediate-risk group. Second, cisplatin-based
chemotherapy usually has been accepted as effective
adjuvant therapy against cervical cancer. However, the
optimal platinum-based combination treatments in
adjuvant concurrent chemoradiation (CCRT) is still
under investigation. Topotecan is an agent with anti-
neoplastic activity on recurrent or metastatic cervical
cancer and has been shown acceptable toxicity and
good response rates in previous studies as a combined
regimen with cisplatin [13,14]. Consequently, topotecan/
cisplatin was chosen as concurrent chemotherapy regimen
in our study.
The aim of the present study (ClinicalTrials.gov
Identifier: NCT01418859) was to investigate the efficacy
and safety of CCRT with topotecan/cisplatin as adjuvant
therapy after radical hysterectomy for cervical cancer
patients with intermediate-risk factors.Methods
Eligibility
Patients from First Affiliated Hospital of Xi’an Jiaotong
University who had undergone radical surgery for clin-
ical stage IB- IIA carcinoma of the cervix were enrolled
in the study from September 2011 to August 2013.
Radical hysterectomy and pelvic lymphadenectomy, with
or without para-aortic lymphadenectomy was performed
either via laparotomy or laparoscopy, according to the
Gynecologic Procedures Manual of the GOG, which
outlined minimum surgical requirements for study
entry [15]. Patients who had biopsy-confirmed or were
strongly suspected of para-aortic node metastasis on
preoperative CT or MRI scan were not eligible. A total
of 39 patients who had squamous carcinoma, adenocar-
cinoma, or adenosquamous carcinoma were eligible and
all had histologically confirmed the following intermedi-
ate risk factors: greater than one-third stromal invasion,
lymphovascular space involvement, or tumor size ≥4 cm.
Patients who had high-risk factors, such as positive pel-
vic lymph nodes, parametrial involvement, or positive
surgical margins, were excluded. Registration was re-
quired within 4-6 weeks of surgery, with RT to begin
within 3-5 working days of registration.
Patients were required to have an Eastern Cooperative
Oncology Group performance status of 0 to 2. The re-
search was approved by Institutional Ethics Committee
of First Affiliated Hospital of Xi’an Jiaotong University.
The written informed consent was obtained from each
patient.
Treatment
Following registration, patients were randomly assigned
to one of three treatment arms including arm A
(radiotherapy only), arm B (concurrent chemoradio-
therapy only), and arm C (concurrent chemoradiotherapy
with following consolidation chemotherapy).
All the patients underwent external beam radiation
therapy to whole pelvis, but no brachytherapy. The ex-
ternal RT was given using IMRT or 3D-CRT with x-ray
energy of 10 MV and consisted of 180-200 cGy per day
on days 1 to 5 of each week, for a total of 25 fractions.
Radiation dose ranged from 4500 to 5000 cGy. Radiation
therapy was withheld if a patient had an absolute neu-
trophil count < 500/mm3, and delays of up to 5 days
were also allowed in the event of radiation-related
gastrointestinal or genitourinary toxicity.
One cycle of chemotherapy was administered at the
second week concurrent with RT as follows:topotecan
0.75 mg/m2 intravenously during 30 minutes, followed
by cisplatin 25 mg/m2 intravenously for days 1, 2 and 3.
Three cycles of consolidation chemotherapy were per-
formed followed by first concurrent chemotherapy at the
6th, 10th and 14th weeks. The regimen was topotecan
Table 1 Patient characteristics
Clinicopathologic
variables
RT CCRT CCRT + CT P value
(N = 13) (N = 15) (N = 5)
Age
≤50 3 4 1 0.558
>50 10 11 4
Cell type
Squamous 12 13 5 0.329
Non-squamous 1 2 0
Tumor grade
I 1 1 0 0.583
II 9 10 3
III 3 4 2
Stage
IB1 1 2 0 0.782
IB2 8 9 3
IIA1 2 3 1
IIA2 2 1 1
Risk factors
LTS only 1 2 0 0.489
DSI only 7 7 3
LVSI only 0 0 0
LTS + DSI 5 5 2
LTS + LVSI 0 0 0
DSI + LVSI 0 1 0
LTS + DSI + LVSI 0 0 0
Abbreviations: RT radiotherapy, CCRT chemoradiotherapy,
CCRT + CT chemoradiotherapy plus consolidation chemotherapy,
LTS large tumor size, DSI deep stromal invasion, LVSI lymphovascular
space involvement.
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followed by cisplatin 25 mg/m2 for day 1, 2 and 3, repeated
every 21 days.
The protocol is registered with ClinicalTrials.gov,
number NCT01418859.
Treatment modifications
Dose adjustment was based on the greatest toxicity
grade, using the National Cancer Institute Common
Toxicity Criteria for Adverse Events (version 3). Chemo-
therapy was performed, providing the patient’s absolute
neutrophil count recovered to ≥1500/mm3 and platelets
were ≥100,000/mm3 on the day of re-treatment. The cis-
platin dose was decreased by 50% for grade 2 renal tox-
icity and held for the present cycle for grade 3 to 4 renal
toxicity on the scheduled day of re-treatment. While
topotecan was reduced by 20% for grade 3 and by 40%
for grade 4 interval hematologic toxicity for the entire
course of therapy. No dose reductions were allowed for
grade 1 or 2 interval hematologic toxicity. Chemother-
apy was also withheld until resolution of any grade 3 or
4 nonhematologic toxicity.
Analysis
Between the radiotherapy, chemoradiotherapy, chemora-
diotherapy plus consolidation chemotherapy groups, the
differences of clinicopathologic variables were evaluated
using the chi-square test, Fisher’s exact test, or linear by
linear association method for categorical variables. Ad-
verse event rates of the three groups were compared
using Fisher’s exact test. All analyses were performed
using SPSS 17.0 software (SPSS Inc., Chicago, IL) and
P values less than 0.05 were considered significant.
Results
Treatment and compliance
Of the remaining 39 eligible patients (stage IB-IIA), 14
were randomly allocated to receive radiotherapy only
(arm A), 15 were randomly allocated to receive chemo-
radiotherapy (arm B) and 10 were randomly allocated to
receive chemoradiotherapy plus consolidation chemo-
therapy (arm C). Among patients randomly allocated to
receive radiotherapy, chemoradiotherapy or chemoradio-
therapy plus consolidation chemotherapy, patient char-
acteristics were well-balanced (Table 1).
Fifteen percent of patients (6 of 39) did not complete
protocol therapy. Three patients discontinued planned
therapy in arm C because of persistent grade 4 neutro-
penia toxicity. Other three patients also did not
complete the therapy, including one in arm A because of
costs of treatment and two in arm C because of refusal
to continue. Therefore, 33 patients, 13 in arm A, 15 in
arm B, and 5 in arm C completed treatment protocol
and were analysed.Radiotherapy was withheld in 12 patients owing to
grade 4 hematologic toxicity or for 5 to 9 days until neu-
tropenia recovered to grade 2. Chemotherapy was sus-
pended because of grade 4 hematologic toxicity in 7
patients during consolidation chemotherapy. Specially,
three patients discontinued planned therapy in arm C
because of persistent grade 4 neutropenia.
Recurrence-free survival and overall survival of each
group were not analyzed on account of a median follow-
up of only 16 months.
Toxicity
Adverse events are summarized in Table 2. Hematologic
toxicity was more frequent and more severe in the
CCRT and CCRT + CT arms compared with the RT arm.
Grade 3 and 4 neutropenia occurred in 46.7% (7/15) of
patients who received CCRT and 100.0% (5/5) of pa-
tients who received CCRT + CT but in only 15.4% (2/13)
of those who received RT only (P = 0.002). Febrile
Table 2 Adverse events by treatment







3 4 3 4 3 4
Neutropenia 2 0 2 5 3 2 0.002
Anemia 1 0 2 0 1 0 0.128
Thrombocytopenia 1 0 3 1 1 1 0.079
Nausea/vomiting 1 0 2 0 1 0 0.446
Diarrhea 1 0 2 1 1 0 0.383
Genitourinary 1 0 1 0 1 0 0.673
Neurotoxicity 0 0 0 0 0 0 1
Renal 0 0 0 0 0 0 1
Hepatic 0 0 1 0 1 0 0.339
Abbreviations: RT radiotherapy, CCRT chemoradiotherapy,
CCRT + CT chemoradiotherapy plus consolidation chemotherapy.
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with CCRT + CT and 14.3% (1/7) of those who received
CCRT. Grade 3 and 4 thrombocytopenia occurred in
26.7% (4/15) of patients who received CCRT and 40.0%
(2/5) of patients who received CCRT + CT versus only
7.7% (1/13) of those who received RT. (P = 0.079). Dose
reductions were required for all the 5 patients in
CCRT + CT group in a subsequent cycle. However,
there were no significant differences in grade 3 or 4
non-hematologic toxicities between the three groups.
Diarrhea grades 3 and 4 were observed in1 (7.6%)
patients of RT group, in 3 (20.0%) patients of CCRT
group and in 1 (20.0%) patient of CCRT + CT group,
respectively (P = 0.383). Genitourinary grades 3 and 4
occurred in only 1 patient in each arms (P = 0.673).
Discussion
Radical hysterectomy with pelvic lymphadenectomy has
been widely accepted as the treatment in patients with
IB-IIA cervical cancer. Because 10-20% of the patients
recurred after radical surgery, efforts to reduce recur-
rences and improve survival in patients with cervical
cancer have been made [11].
Since the beneficial effect of adjuvant concurrent che-
moradiation for cervical patients with high-risk factors
was proven in prospective studies from the Gynecologic
Oncology Group (GOG) and the Radiation Therapy
Oncology Group [3,6], concurrent chemoradiation is
considered the optimum postoperative adjuvant ther-
apy in patients with high-risk factors. However, in a
Gynecologic Oncology Group study(GOG 92) that
attempted to investigate the role of adjuvant radiotherapy
(RT) in the intermediate-risk group, 277 cervical cancer
patients with intermediate risk factors were randomized
to the no further treatment (NFT) or RT group [9]. Inthose who met the GOG criteria, which defined the
intermediate-risk group using a three-factor model of
a combination of intermediate risk factors (capillary
lymphatic space involvement, stromal invasion depth,
and tumor size), a statistically significant reduction of
risk of recurrence and an increase in recurrence free sur-
vival was found in the RT group compared with the NFT
group. Since the efficacy of adjuvant radiation for pa-
tients with intermediate-risk factors were demonstrated
in the previous trials [5,9,11,12], radiation is the standard
adjuvant therapy in patients with intermediate-risk fac-
tors. However, as shown in the GOG 92 trial, the recur-
rence rate of the intermediate-risk group was 27.9% in
the NFT group, comparable to that of patients with high-
risk factors. Furthermore, even though the recurrence
rate was reduced with the use of adjuvant RT, the rate of
recurrence was still significant (15%, 21 of 137 cases) in
the RT group [11]. In addition, in the study of Tuipae S
et al., distant recurrence was still the major pattern of
treatment failure after adjuvant radiotherapy in cervical
cancer with intermediate risk factors [12].
Maybe the adjuvant chemoradiation have more benefi-
cial effect over radiation only for patients with inter-
mediate risk factors. An early study reported that, in
patients with LVSI and deep stromal invasion, the 3-year
RFS (recurrence-free survival) of the concurrent chemo-
radiation group was significantly greater than that of the
radiation group [16]. Some retrospective studies in re-
cent years also have showed the benefit of adding
chemotherapy to radiation in patients with intermediate-
risk factors and the levels of all toxicities were accept-
able [17-20]. A statistically significant difference was
found in the 3-year RFS rate among the no further treat-
ment, RT, and CCRT groups (67.5%, 90.5%, and 97.5%,
respectively; p <0 .05) in the study of Ryu SY et al. [18].
Okazawa M et al. reviewed the medical records of 316
patients with stage IB1-IIB cervical cancer who had been
treated with adjuvant radiotherapy (RT) (n = 124, RT
group) or adjuvant CCRT (n = 192, CCRT group) after
radical hysterectomy and found that CCRT was superior
to RT with regard to recurrence rate and PFS in patents
with 2 or more intermediate risk factors, while the
patients with only 1 intermediate risk factor showed no
survival benefit of CCRT over RT [20]. However, due to
the lack of randomized trials, the benefit of concurrent
chemoradiation over radiation in cervical cancer patients
with intermediate-risk factors remains unclear.
Furthermore, adjuvant CCRT modalities for intermedi-
ate risk tumors have been debating. Weekly cisplatin or
cisplatin plus 5-fluorouracil (5- FU) every 3 weeks has
been widely used as the preferred treatment with CCRT
in previous studies. Nevertheless, these standard regi-
mens had some disadvantages [21,22]. For instance, the
weekly cisplatin frequently caused a treatment delay due
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weekly visit to the hospital was inconvenient. In
addition, 5-fluorouracil/cisplatin, a five-day regimen,
caused more discomfort to patients and sometimes
caused intractable nausea and vomiting. While previous
studies using topotecan/cisplatin for patients with recur-
rent or metastatic cervical cancer have shown acceptable
toxicity and good response rates. Thus, topotecan with
cisplatin was chosen as concurrent chemotherapy regimen
in our study.
Recently, cisplatin-based consolidation chemotherapy
after CCRT has been reported to enhance local control
and promote eradication of possible distant micro-
metastases in locally advanced cervical cancer by phase
II studies [23-25]. These promsing results suggested that
consolidation chemotherapy after primary CCRT may
play a role independent of the radiotherapy in locally
advanced cervical carcinoma. Furthermore, for high-risk
patients after radical surgery, the continuation of
chemotherapy (cisplatin 70 mg/m2 on day 1 and 5-FU
1000 mg/m2/d for 5 days) for three to four cycles re-
sulted in improved patient survival compared with the
survival of patients who receive only one or two courses
of chemotherapy(P < 0.03) in the study of Peters 3rd WA
et al. [3]. It was not determined from their study
whether the effect of the chemotherapy was as a radi-
ation sensitiser or as a systemic chemotherapy with
elimination of possible micrometastasis, or both. In con-
trast, Kim HS et al. found that consolidation chemother-
apy after CCRT using paclitaxel and carboplatin failed to
improve PFS and OS as compared to CCRT-only in pa-
tients with high-risk early-stage cervical cancer who
underwent surgical treatment (3-year PFS, 62.7% vs.
88.2%, respectively; 3-year OS, 90.9% vs. 97.3%, respect-
ively) [26]. However, is there any role for consolidation
chemotherapy following CCRT in intermediate-risk cer-
vical cancer patients? We designed arm C(CCRT + CT)
to examine whether the addition of consolidation
chemotherapy to CCRT could improve the progression-
free survival and overall survival in patients with
intermediate-risk factors after radical surgery.
On account of a median follow-up of only 16 months,
RFS (recurrence-free survival) and OS (overall survival)
of each group were not analyzed in the present study.
Another issue that must be discussed is complications of
these adjuvant therapies following radical surgery. Al-
though cisplatin-based chemotherapy concurrent with
RT is a standard treatment modality for advanced-stage
cervical cancer, many physicians are still reluctant to
treat the intermediate-risk group with CCRT. Because
combined modalities are more likely to result in serious
complications. As is known, radiotherapy after radical
hysterectomy has been reported to be associated with
high incidence of complications and many of theseconditions are very tragic and irreversible and result in
poor quality of life [27,28]. Barter et al. observed that
30% of patients treated with radiation after radical
hysterectomy had serious complications, such as gastro-
intestinal and genitourinary complications and leg
lymphedema et al. [28]. Meanwhile, the major toxicities
of combined chemotherapy were bone marrow depres-
sion, mild to moderate gastrointestinal troubles, mild to
moderate nephrotoxicities, total alopecia (in etoposide-
cisplatin group), relatively low incidence of neurotoxic-
ities and hepatotoxicities, rare incidence of pulmonary
and cardiac toxicities and some reported secondary ma-
lignancies (acute leukemia and some solid tumors). In
previous studies the levels of all these toxicities of com-
bined chemotherapy were acceptable and most are re-
versible and transient [17-20]. Nevertheless, the results
of the present study found that hematologic toxicity was
significantly more frequent and more severe in the
CCRT and CCRT + CT arms compared with the RT arm.
Grade 3 and 4 neutropenia occurred in 46.7% (7/15) of
patients who received CCRT and 100.0% (5/5) of pa-
tients who received CCRT + CT but in only 15.4% (2/13)
of those who received RT only (P = 0.002). Especially,
three patients discontinued planned therapy in arm C
because of persistent grade 4 neutropenia toxicity.
Although topotecan with cisplatin has been shown
acceptable toxicity and good response rates in recur-
rent or metastatic cervical cancer, similar to the
study of Long HJ 3rd et al., which reported that the
combination of topotecan-cisplatin resulted in sub-
stantial neutropenia (70% vs 1.4%) compared with
single cisplatin agent, and nearly 18% of patients in
the topotecan-cisplatin arm experienced febrile neu-
tropenia in patients with advanced (stage IVB), recur-
rent or persistent carcinoma of the uterine cervix,
topotecan plus cisplatin chemotherapy concurrent
with RT in our study also showed severe hematologic
toxicity [14]. Therefore, we closed the clinical trial ahead
of schedule.
Although our study showed severe hematologic tox-
icity of concurrent chemoradiation with topotecan and
cisplatin in safe dose to radiation in patients with
intermediate-risk factors, the efficacy and toxicity are
still unclear. As we mentioned in the results, the number
of patients in the different group is small (14 in group
A, 15 in group B and 10 in group C) because the study
closed ahead of schedule and the media follow-up time
is only 16 months. In spite of these limitations, due to
topotecan has been identificated as an antineoplastic
agent with cisplatin in cervival cancer, a trial with
optimal dose, sufficient size and long term follow-up
would be necessary to demonstrate the advantage of
concurrent chemoradiation in patients with intermediate-
risk factors.
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To conclude that chemoradiotherapy maybe the better
adjuvant therapy than radiation in patients with
intermediate-risk factors, but the benefit of chemoradio-
therapy should overweigh the cost of adverse effects.
The present study showed severe hematologic toxicity in
the chemoradiotherapy with topotecan and cisplatin
groups and was closed ahead of schedule. Therefore, the
optimal platinum-based adjuvant chemoradiotherapy in
cervical cancer patients with intermediate risk factors is
still under investigation especially and the final conclu-
sion regarding the role of chemoradiotherapy should be
withheld.
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